- Home
- NYC vs CGTX Comparison
NYC vs CGTX Comparison
Compare NYC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- CGTX
- Stock Information
- Founded
- NYC 2013
- CGTX 2007
- Country
- NYC United States
- CGTX United States
- Employees
- NYC N/A
- CGTX N/A
- Industry
- NYC Real Estate
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- NYC Finance
- CGTX Health Care
- Exchange
- NYC Nasdaq
- CGTX Nasdaq
- Market Cap
- NYC 24.9M
- CGTX 25.1M
- IPO Year
- NYC N/A
- CGTX 2021
- Fundamental
- Price
- NYC $15.71
- CGTX $0.57
- Analyst Decision
- NYC
- CGTX Strong Buy
- Analyst Count
- NYC 0
- CGTX 4
- Target Price
- NYC N/A
- CGTX $2.83
- AVG Volume (30 Days)
- NYC 7.6K
- CGTX 16.9M
- Earning Date
- NYC 08-08-2025
- CGTX 08-07-2025
- Dividend Yield
- NYC N/A
- CGTX N/A
- EPS Growth
- NYC N/A
- CGTX N/A
- EPS
- NYC N/A
- CGTX N/A
- Revenue
- NYC $58,397,000.00
- CGTX N/A
- Revenue This Year
- NYC $8.40
- CGTX N/A
- Revenue Next Year
- NYC $1.62
- CGTX N/A
- P/E Ratio
- NYC N/A
- CGTX N/A
- Revenue Growth
- NYC N/A
- CGTX N/A
- 52 Week Low
- NYC $7.55
- CGTX $0.22
- 52 Week High
- NYC $16.30
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- NYC 76.25
- CGTX 63.33
- Support Level
- NYC $14.64
- CGTX $0.52
- Resistance Level
- NYC $16.30
- CGTX $1.04
- Average True Range (ATR)
- NYC 1.09
- CGTX 0.09
- MACD
- NYC 0.33
- CGTX 0.04
- Stochastic Oscillator
- NYC 89.80
- CGTX 40.18
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.